Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
· cnbc.com
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Novo shares fell as much as 7% on Monday after the company laid out new growth ambitions to revive its fortunes in the booming obesity drug market.
The Danish ...